王建澍, 移志刚, 蒲彦川, 宋建民, 耿彬, 康雅琼, 马淑萍, 安丽萍, 夏亚一. ERK5和MMP-9在骨肉瘤中的表达及其临床意义[J]. 中国肿瘤临床, 2017, 44(14): 689-694. DOI: 10.3969/j.issn.1000-8179.2017.14.146
引用本文: 王建澍, 移志刚, 蒲彦川, 宋建民, 耿彬, 康雅琼, 马淑萍, 安丽萍, 夏亚一. ERK5和MMP-9在骨肉瘤中的表达及其临床意义[J]. 中国肿瘤临床, 2017, 44(14): 689-694. DOI: 10.3969/j.issn.1000-8179.2017.14.146
shu
WANG Jianshu, YI Zhigang, PU Yanchuan, SONG Jianmin, GENG Bin, KANG Yaqiong, MA Shuping, WANG Liping, XIA Yayi. ERK5 and MMP-9 expression levels in osteosarcoma and their clinical significance[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 44(14): 689-694. DOI: 10.3969/j.issn.1000-8179.2017.14.146
Citation: WANG Jianshu, YI Zhigang, PU Yanchuan, SONG Jianmin, GENG Bin, KANG Yaqiong, MA Shuping, WANG Liping, XIA Yayi. ERK5 and MMP-9 expression levels in osteosarcoma and their clinical significance[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 44(14): 689-694. DOI: 10.3969/j.issn.1000-8179.2017.14.146
shu

ERK5和MMP-9在骨肉瘤中的表达及其临床意义

ERK5 and MMP-9 expression levels in osteosarcoma and their clinical significance

    摘要
  • 摘要:
      目的  探讨细胞外信号调节激酶5（extracellular signal-regulated kinase 5，ERK5）蛋白和基质金属蛋白酶-9（matrix metallo proteinase-9，MMP-9）在骨肉瘤组织中的表达及其临床意义。
      方法  选取71例骨肉瘤组织和40例正常骨组织，采用免疫组织化学法检测ERK5和MMP-9的表达，并分析ERK5和MMP-9的表达与骨肉瘤患者临床病理特征及预后之间的关系。
      结果  骨肉瘤组织中ERK5和MMP-9阳性表达率分别为85.9%（61/71）、74.65%（53/71），均明显高于正常骨组织中阳性表达率12.5%（5/40）、10.0%（4/40），差异均具有统计学意义（均P < 0.05）。ERK5和MMP-9的阳性表达与Enneking分期和转移相关（均P < 0.05）。Ka-plan-Meier生存分析显示在骨肉瘤组织中ERK5、MMP-9的阳性表达组患者生存时间均短于阴性表达组（均P < 0.05）。单因素Cox回归分析发现，肿瘤大小、Enneking分期、转移、ERK5和MMP-9阳性表达与患者总生存时间相关（均P < 0.05）；多因素分析证实Enneking分期、转移、ERK5和MMP-9蛋白的阳性表达可作为骨肉瘤患者独立的预后因子（均P < 0.05）。
      结论  ERK5和MMP-9在骨肉瘤组织中高表达，与骨肉瘤的病理特征及预后相关；二者可能在骨肉瘤发生发展的过程中起着重要作用。

     

    Abstract:
      Objective  To investigate the extracellular signal-regulated kinase 5 (ERK5) and matrix metallo proteinase-9 (MMP-9) expression levels in osteosarcoma tissues and their clinical significance.
      Methods  The ERK5 and MMP-9 expression levels in 71 specimens of osteosarcoma tissue and 40 specimens of normal bone tissue were detected by immunohistochemistry. The relationship between ERK5 and MMP-9 expression levels, their clinical characteristics, and prognosis of patients with osteosarcoma were analyzed.
      Results  The positive expression of ERK5 and MMP-9 in osteosarcoma tissues was 85.9% (61/71) and 74.65% (53/71), respectively, which were significantly higher than those in normal bone tissues at 12.5% (5/40) and 10.0% (4/40) (all P < 0.05). The positive expression of ERK5 and MMP-9 was associated with Enneking stage and metastasis (all P < 0.05). Kaplan-Meier analysis showed that the survival duration of patients with positive ERK5 and MMP-9 expression levels was shorter than those of the patients in the negative expression groups (all P < 0.05). Univariate analysis of COX proportional hazards regression model revealed that tumor size, Enneking stage, metastasis, and positive ERK5 and MMP-9 expression levels are relevant to the overall survival of patients with osteosarcoma (all P < 0.05). Multivariate analysis of COX proportional hazards regression model confirmed that Enneking stage, metastasis, and positive ERK5 and MMP-9 expression levels can act as independent prognostic factors for osteosarcoma patients (all P < 0.05).
      Conclusion  The ERK5 and MMP-9 expression levels are high in osteosarcoma tissues and are related to the clinical characteristics and prognosis of patients with osteosarcoma. Thus, ERK5 and MMP-9 expression levels may play important roles in osteosarcoma development and progression.

     

    • HTML全文
    • 参考文献(24)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回